JAMA Neurology Examines Rituxan

Wednesday, January 24, 2018

This study, recently published in the journal JAMA Neurology, examined the use of Rituximab as a first-line MS treatment in Sweden. Rituximab is already extensively used in Sweden but this study showed the improved efficacy and safety of using Rituximab as a first MS treatment as compared to other MS drugs. However, as Rituximab is not FDA-approved in the United States for MS, its use early in MS is limited due to restrictions by insurance companies.

https://www.medpagetoday.com/neuro…/multiplesclerosis/70393…

News Archive

Tisch MS Research Center of New York

521 West 57th Street
4th Floor
New York, NY 10019
(646) 557-3900

Eventbrite - Tisch MS Research Center 21st Annual MS Patient Symposium

Support Tisch MS

Support Tisch MS and our innovative research leading to treatments that improve the lives of patients.